Latest Alcidion (ASX:ALC) News

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

Alcidion Group has been named preferred supplier for a major UK hospital's Electronic Patient Record system, driving a 40% jump in contracted revenue and a robust cash position in Q2 FY26.

Alcidion has been named the preferred supplier for University Hospitals Sussex's new Electronic Patient Record system, with a contract expected to exceed A$35 million over seven years. This deal builds on an existing partnership and marks a significant expansion for Alcidion in the UK healthcare IT market.

Alcidion Group has expanded its contract with Leidos Australia, adding $12.3 million in value and increasing annual recurring revenue by $2.5 million through to 2028.

Alcidion Group Limited has reported a robust start to FY26, posting $8.2 million in new sales and significantly improving its operating cash flow. The company reaffirms its guidance for positive EBITDA and cash flow for the full year.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

Alcidion Group has expanded its contract with North Cumbria Integrated Care NHS Foundation Trust to integrate MediViewer into its Miya Precision electronic patient record system, enhancing access to scanned and historical documents.

Alcidion Group Limited has delivered a record FY25 with $40.8 million in revenue and underlying EBITDA of $5.1 million, driven by a landmark $39 million UK electronic patient record contract and strong recurring revenue growth.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

Alcidion Group Limited has reversed a significant loss from the previous year, reporting a $1.65 million profit for FY25 driven by new sales and a leaner cost base.

Alcidion Group Limited has reported its strongest quarter ever with record operating cashflow and a doubling of new sales, reaffirming its positive outlook for FY25.

Alcidion Group Limited has upgraded its full-year EBITDA guidance for FY25, now expecting earnings to exceed $4.5 million, driven by contract expansions, cost discipline, and favorable currency effects.